Harvard Apparatus Regenerative Technology, Inc.

For the period ended Mar 31, 2025. Filed May 14, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 14, 2025

HRGNStored price and day change unavailable

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Cash Flows (Unaudited)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

	Three Months Ended
	March 31,
	2025	2024
OPERATING ACTIVITIES
Net loss	$(1,659)	$(2,030)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation expense	485	560
Depreciation	2	6
Amortization of operating lease right-of-use assets	23	27
Changes in operating assets and liabilities:
Accounts receivable	227	(3)
Inventory	32	6
Prepaid research and development	—	51
Prepaid expenses and other current assets	(85)	(48)
Long-term prepaid contracts	70	—
Accounts payable	3	445
Operating lease liability	(22)	(27)
Accrued and other current liabilities	(38)	53
Deferred revenue	299	—
Insurance premium financing payable	(95)	—
Net cash used in operating activities	(758)	(960)
FINANCING ACTIVITIES
Advance from private placement	—	301
Proceeds from convertible debt – related party	—	500
Net cash provided by financing activities	—	801
Effect of exchange rate changes on cash	—	(1)
Net decrease in cash and cash equivalents	(758)	(160)
Cash and cash equivalents at the beginning of the year	2,486	432
Cash and cash equivalents at the end of the period	$1,728	$272
SUPPLEMENTAL INFORMATION
Interest paid in cash	$2	$9

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.